Skip to content
value.today

Adamis Pharmaceuticals Corp

Formerly Cellegy Pharmaceuticals Inc.

Total raised
$16 M
3 rounds on record
Latest round
$6 M
Feb 2020
First round on record
Jun 2011
Today
Private
See the company page

Adamis Pharmaceuticals Corp is listed today as Adamis Pharmaceuticals Corporation: market value, financials and filings are on its company page.

Funding rounds

3 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Adamis Pharmaceuticals Corp
MonthRaisedRaiseSizeInvestorsSoldFiling
Feb 2020$6 MNo. 3$2 to $10 million

Adamis Pharmaceuticals Corp: Raise no. 3, Feb 2020

Investors in this round

2 investors had bought by the notice of Mar 6, 2020: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$6 M of $6 M offered
Smallest investment taken
no minimum stated
What was sold
options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • David J Marguglio · Executive Officer, Director
  • Dennis J Carlo · Executive Officer, Director
  • Karen K Daniels · Executive Officer
  • Robert O Hopkins · Executive Officer · Maxim Group LLC received sales commissions of $403,680 in connection with a concurrent registered direct offering by the
  • Ronald B Moss · Executive Officer
  • Howard C Birndorf · Director
  • Richard C Williams · Director
  • Roshawn C Blunt · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Maxim Group LLC (CRD 120708) · New York, New YorkSold in CA, and outside the US

Remarks in the notice

  • On fees: “Maxim Group LLC received sales commissions of $403,680 in connection with a concurrent registered direct offering by the Company.”

Signed by Robert O. Hopkins, Chief Financial Officer. Source: SEC Form D, newest notice filed Mar 6, 2020. Read the notice at the SEC.

optionsSEC
Jun 2013$7 MNo. 2$2 to $10 million

Adamis Pharmaceuticals Corp: Raise no. 2, Jun 2013

Investors in this round

11 investors had bought by the notice of Jul 11, 2013: 11 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$7 M of $7 M offered
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities, other: Convertible Debentures
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
$190,000
Paid to its own people
$700,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks finders' fees and payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Craig A Johnson · Executive Officer
  • David J Marguglio · Executive Officer
  • Dennis J Carlo · Executive Officer, Director
  • Robert O Hopkins · Executive Officer, Director
  • Thomas K Moll · Executive Officer
  • Karen K Daniels · Director
  • Kenneth M Cohen · Director
  • Tina S Nova, Ph. D. · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • LifeTech Capital, a division of Aurora Capital LLC · broker-dealer Aurora Capital LLC (CRD 37924) · New York, New YorkSold in CA, MA, NY

Signed by Robert O. Hopkins, Chief Financial Officer. Source: SEC Form D, newest notice filed Jul 11, 2013. Read the notice at the SEC.

debt, optionsSEC
Jun 2011$3 MNo. 1$2 to $10 million

Adamis Pharmaceuticals Corp: Raise no. 1, Jun 2011

Investors in this round

2 investors had bought by the notice of Apr 6, 2012: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$3 M of $3 M offered
Smallest investment taken
no minimum stated
What was sold
equity, debt, securities to be acquired by exercising them
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
No revenue
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • David J. Marguglio · Executive Officer, Director
  • Dennis J. Carlo · Executive Officer, Director
  • Karen K. Daniels · Executive Officer
  • Robert O Hopkins · Executive Officer
  • Craig S. Johnson · Director
  • Kenneth M. Cohen · Director
  • Tina S. Nova, Ph.D · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Robert O. Hopkins, Chief Financial Officer. Source: SEC Form D, newest notice filed Apr 6, 2012. Read the notice at the SEC.

equity, debtSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Adamis Pharmaceuticals Corp chose not to state its revenue in its newest notice of a funding round (Mar 2020).

    SEC Form D · Mar 2020

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Mar 2020

That is all the official record says: Adamis Pharmaceuticals Corp has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services of Adamis Pharmaceuticals Corp are on record.

Investors#

No investor of Adamis Pharmaceuticals Corp is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 11 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Adamis Pharmaceuticals Corp
NameRoleNamed in
David J MarguglioExecutive officerMar 2020
Dennis J CarloExecutive officerMar 2020
Karen K DanielsExecutive officerMar 2020
Robert O HopkinsMaxim Group LLC received sales commissions of $403,680 in connection with a concurrent registered direct offering by theMar 2020
Ronald B MossExecutive officerMar 2020
Craig A JohnsonExecutive officerJul 2013
Thomas K MollExecutive officerJul 2013
David J. MarguglioExecutive officerApr 2012
Dennis J. CarloExecutive officerApr 2012
Karen K. DanielsExecutive officerApr 2012
David J MarguglioDirectorMar 2020
Dennis J CarloDirectorMar 2020
Howard C BirndorfDirectorMar 2020
Richard C WilliamsDirectorMar 2020
Roshawn C BluntDirectorMar 2020
Karen K DanielsDirectorJul 2013
Kenneth M CohenDirectorJul 2013
Robert O HopkinsDirectorJul 2013
Tina S Nova, Ph. D.DirectorJul 2013
Craig S. JohnsonDirectorApr 2012
David J. MarguglioDirectorApr 2012
Dennis J. CarloDirectorApr 2012
Kenneth M. CohenDirectorApr 2012
Tina S. Nova, Ph.DDirectorApr 2012

About

Pharmaceutical company in San Diego, United States.